RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2023

Aug 9, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2023-08-07

Reporting Person: Lee Jennifer Kayden (EVP, Head of North America)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-08-07	Common Stock	M	8591	$6.80	Acquired	14517	Direct
2023-08-07	Common Stock	S	11223	$24.1778	Disposed	3294	Direct
2023-08-09	Common Stock	M	1718	$6.80	Acquired	5012	Direct
2023-08-09	Common Stock	S	1718	$24.66	Disposed	3294	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-08-07	Stock Option (Right to Buy)	$6.80	M	8591	Disposed	2032-02-08	Common Stock (8591)	Direct
2023-08-09	Stock Option (Right to Buy)	$6.80	M	1718	Disposed	2032-02-08	Common Stock (1718)	Direct

Footnotes

F1: Includes 986 shares acquired under Issuer's Employee Stock Purchase Plan on February 28, 2023.

F2: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023.

F3: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.